IM Cannabis Corp. (NASDAQ: IMCC) (CSE: IMCC) Q3 2022 revenues were CA$14.2 million ($10.7 million), compared to CA$8.0 million on Q3 2021, an increase of 78%, representing a 12% sequential organic growth. The increase in revenues is primarily attributed to the increase in the quantity of medical cannabis products sold, as well as from the higher average selling price per gram the company realized from its portfolio of branded cannabis products in Israel.

Q3 2022 Financial Results

Full story available on Benzinga.com